课题基金 / 基金详情

UAC 1117 CAMPATH 1H GIVEN FIVE TIMES WEEKLY IN NON-HODGKINS LYMPHOMA

UAC 1117 CAMPATH 1H GIVEN FIVE TIMES WEEKLY IN NON-HODGKINS LYMPHOMA
UAC 1117 CAMPATH 1H 每周给予非霍奇金淋巴瘤五次
批准号：
3783544
负责人：
MANSOOR N SALEH
金额：
$0.0万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3783544
关键词：
CD antigens antineoplastics clinical trials dosage drug administration rate /duration drug adverse effect human subject human therapy evaluation neoplasm /cancer immunotherapy nonHodgkin's lymphoma

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients received five times weekly doses starting at 1mg/dose and escalating to 5mg/dose and 25mg/dose. Toxicity consisted of fever, rigors, and increased susceptibility to infections. This study has been closed due to completion of patient accrual. A phase II study is planned at the dose of 25mg/dose administered three times weekly.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金